PHARMA4L
ActivePHARMA4L is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.36M and a net result of €243k. Equity is growing by ~21.6% per year across the filed fiscal years. Its solvency ranks better than 61% of 5394 sector peers (fiscal year 2025). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals.
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 9 filingsDeviation from the deadline
2025
31 d late
2024
92 d late
2023
30 d late
2022
31 d late
2021
53 d late
2020
31 d late
2019
81 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
05-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€1.36M▲ 21.8%
2024 · €1.11M
2021: €614k
2022: €843k
2023: €921k
2024: €1.11M
2021 → 2025
Net result
€243k▲ 26.4%
2024 · €192k
2021: €211k
2022: €229k
2023: €78k
2024: €192k
2021 → 2025
Total assets
€2.14M▲ 16.3%
2024 · €1.84M
2021: €1.88M
2022: €1.85M
2023: €1.83M
2024: €1.84M
2021 → 2025
Solvency
63.5%▲ 2.9pp
2024 · 60.6%
2021: 32.6%
2022: 45.5%
2023: 50.5%
2024: 60.6%
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€614k-€843k▲ 37.2%€921k▲ 9.3%€1.11M▲ 20.9%€1.36M▲ 21.8%
Operating result€128k-€128k▼ 0.3%€127k▼ 0.5%€120k▼ 5.9%€166k▲ 38.8%
Net result€211k-€229k▲ 8.4%€78k▼ 65.7%€192k▲ 145%€243k▲ 26.4%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 39% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.14M
Fixed assets
€2.00M▲ 15.3%
Current assets
€141k▲ 32.8%
Equity and liabilities €2.14M
Equity
€1.36M▲ 21.8%
Debt
€781k▲ 7.8%
The debt ratio falls from 39.4% to 36.5%: equity grows faster than debt.
Key figures and ratios
Solvency
63.5%▲
2024 · 60.6%
ROE
17.9%▲
2024 · 17.3%
ROA
11.4%▲
2024 · 10.5%
Debt
€781k▲
2024 · €724k
Debt ≤ 1 year
€562k▲
2024 · €392k
Debt > 1 year
€208k▼
2024 · €320k
Income taxes
€56k▲
2024 · €41k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Total assets
20/58€1.84M€2.14M▲
Fixed assets
21/28€1.73M€2.00M▲
Tangible fixed assets
22/27-€264k
Financial fixed assets
28€1.73M€1.73M=
Current assets
29/58€106k€141k▲
Amounts receivable within one year
40/41€67k€122k▲
Cash & bank
54/58€38k€19k▼
Total equity & liabilities
10/49€1.84M€2.14M▲
Equity
10/15€1.11M€1.36M▲
Contributions / capital
10/11€50k€50k=
Reserves
13€1.06M€1.31M▲
Amounts payable
17/49€724k€781k▲
Amounts payable after one year
17€320k€208k▼
Amounts payable within one year
42/48€392k€562k▲
Trade debts payable within one year
44€20k€23k▲
Income statement
Code20242025
Gross operating margin
9900€122k€169k▲
Operating result
9901€120k€166k▲
Financial income
75€124k€153k▲
Financial charges
65€22k€19k▼
Result before taxes
9903€233k€299k▲
Income taxes
67/77€41k€56k▲
Net result for the period
9904€192k€243k▲
Result to be appropriated
9905€192k€243k▲
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
2025
31-12
Financial
Highest result since 2021net €243k ▲26.4%
Operating result €166k, net result €243k, both a record.
31-10
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 92 days late
2024
31-12
Financial
Equity above €1MEq €1.11M ▲20.9%
4 profitable years in a row build equity to €1.11M.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
31-12
Financial
Weakest financial yearnet €78k ▼65.7%
Net result drops to €78k, the lowest in the series; recovery starts the following year.
28-12
State Gazette act
Director changes
Frank Desmet
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 31 days late
2022
22-09
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 53 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 31 days late
2020
20-10
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 81 days late
2019
30-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 30 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 31 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 2 acts read
About the unread acts
Of the 2 Belgian State Gazette acts we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 director, last change in 2023
BRONDEL Bernard
CurrentNon-statutory director · since 28-12-2023
28-12-2023
Appointed as Non-statutory director
Not every act has been read: a resignation may be missing here
1 of this company's 2 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Eeklo · 1 establishment unit since 2016
Ground area
583 m²
Building footprint
260 m²
Volume, LiDAR
2,130 m³
Parcel 43005B0716/00C000, Flanders · tallest building 15.0 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMA4L
since 20162.255.461.816
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 43005B0716/00C000 | Flanders | 583 m² | 1 · 260 m² | 15.0 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Comparable companies · same sector, comparable size
Similar companies · same sector, comparable size
AIM LRE
BE 0784.797.801
Gent · Eq €1.36M
LYNIST
BE 0556.933.121
Berlaar · Eq €1.36M
DE HOEVELEN BEHEER
BE 0866.304.030
Hamont-Achel · Eq €1.36M
Linette
BE 0828.707.028
Boechout · Eq €1.36M
LUCOMA
BE 0823.648.378
Nandrin · Eq €1.36M
Of 24,645 companies in sector 64210 we hold annual accounts for 19,462. 11,899 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded12-07-2016
Fiscal year end31-12
Activities, NACEBEL
64200Holdings
64210Activities of holding companies
Sources
Crossroads Bank for EnterprisesBelgian Official Gazette · 1 actNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 20-07-2026. Scores and ratios are computed by Checked and are not a credit decision.